Role of interferon in melanoma: old hopes and new perspectives. (3rd April 2017)

• Record Type: Journal Article
• Authors: Sanlorenzo, Martina; Vujic, Igor; Carnevale-Schianca, Fabrizio; Quaglino, Pietro; Gammaitoni, Loretta; Fierro, Maria Teresa; Aglietta, Massimo; Sangiolo, Dario
• Is Part Of: Expert opinion on biological therapy. Volume 17:Number 4(2017:Apr.)
• Page Start: 475
• Page End: 483
• Publication Date: 2017-04-03
• Subjects: Interferon -- melanoma -- immunotherapy; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2017.1289169
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction : Interferons (IFNs) play a key role in modulating anti-microbial and antitumor immune responses. In oncology, past attempts to exploit IFNs therapeutically did not fulfill expectations, and had only modest clinical results, mostly limited to adjuvant melanoma treatment. The recent successes of immunotherapy in oncology have brought new attention to the potential of immune-modulatory agents like the IFNs. Areas covered : The authors review the biological effects of IFN on melanoma and immune cells. Then, the authors summarize the clinical results of adjuvant and therapeutic IFN in melanoma, giving focus to possible prognostic factors and new on-going clinical trials. Expert opinion : IFNs offer intriguing opportunities for synergism between conventional treatments and recently introduced molecular-targeted and immunotherapy approaches. However, the full comprehension of all IFN effects and their multiple biologic links is challenging. A strong commitment toward parallel translational research is needed to facilitate the interpretation of IFN's expected and unexpected effects, guiding the rational design of informative clinical studies.